Review



goat anti dpp iv  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    R&D Systems goat anti dpp iv
    Goat Anti Dpp Iv, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 92 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti dpp iv/product/R&D Systems
    Average 99 stars, based on 92 article reviews
    goat anti dpp iv - by Bioz Stars, 2026-03
    99/100 stars

    Images



    Similar Products

    99
    R&D Systems goat anti dpp iv
    Goat Anti Dpp Iv, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti dpp iv/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    goat anti dpp iv - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    90
    R&D Systems goat anti-dpp iv antibody
    Flow chart of procedure for isolating salivary extracellular vesicles. Salivary extracellular vesicles (EVs) were isolated using a combination of size-exclusion chromatography and sequential centrifugation. Human whole saliva was centrifuged, and the supernatant was filtrated and then, concentrated using Amicon Ultra-15. The resulting concentrated solution was applied to a size-exclusion column, and the fractions (Fr.) of EV-I and Fr. EV-II were determined from the measurement of OD280, <t>DPP</t> IV activity, <t>and</t> <t>APN</t> activity. Each fraction was collected, filtered, and concentrated by Amicon Ultra-4 to obtain Fr. EV-I and Fr. EV-II. Each pooled fraction was subjected to sequential centrifugation. The precipitate obtained by centrifugation at 20,000 × g (EV-I or EV-II 20 k-ppt) and the precipitate obtained by centrifugation at 100,000 × g (EV-I or EV-II 100 k-ppt) were further analyzed. After characterizing the protein components (SDS-PAGE and western blotting) and morphological analyses (TEM and DLS), we focused on EV-I 20 k-ppt and EV-II 100 k-ppt and subjected them to proteomic analyses.
    Goat Anti Dpp Iv Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti-dpp iv antibody/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    goat anti-dpp iv antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    93
    R&D Systems goat anti human dpp iv
    Flow chart of procedure for isolating salivary extracellular vesicles. Salivary extracellular vesicles (EVs) were isolated using a combination of size-exclusion chromatography and sequential centrifugation. Human whole saliva was centrifuged, and the supernatant was filtrated and then, concentrated using Amicon Ultra-15. The resulting concentrated solution was applied to a size-exclusion column, and the fractions (Fr.) of EV-I and Fr. EV-II were determined from the measurement of OD280, <t>DPP</t> IV activity, <t>and</t> <t>APN</t> activity. Each fraction was collected, filtered, and concentrated by Amicon Ultra-4 to obtain Fr. EV-I and Fr. EV-II. Each pooled fraction was subjected to sequential centrifugation. The precipitate obtained by centrifugation at 20,000 × g (EV-I or EV-II 20 k-ppt) and the precipitate obtained by centrifugation at 100,000 × g (EV-I or EV-II 100 k-ppt) were further analyzed. After characterizing the protein components (SDS-PAGE and western blotting) and morphological analyses (TEM and DLS), we focused on EV-I 20 k-ppt and EV-II 100 k-ppt and subjected them to proteomic analyses.
    Goat Anti Human Dpp Iv, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti human dpp iv/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    goat anti human dpp iv - by Bioz Stars, 2026-03
    93/100 stars
      Buy from Supplier

    90
    R&D Systems goat anti-dpp-iv antibody
    Flow chart of procedure for isolating salivary extracellular vesicles. Salivary extracellular vesicles (EVs) were isolated using a combination of size-exclusion chromatography and sequential centrifugation. Human whole saliva was centrifuged, and the supernatant was filtrated and then, concentrated using Amicon Ultra-15. The resulting concentrated solution was applied to a size-exclusion column, and the fractions (Fr.) of EV-I and Fr. EV-II were determined from the measurement of OD280, <t>DPP</t> IV activity, <t>and</t> <t>APN</t> activity. Each fraction was collected, filtered, and concentrated by Amicon Ultra-4 to obtain Fr. EV-I and Fr. EV-II. Each pooled fraction was subjected to sequential centrifugation. The precipitate obtained by centrifugation at 20,000 × g (EV-I or EV-II 20 k-ppt) and the precipitate obtained by centrifugation at 100,000 × g (EV-I or EV-II 100 k-ppt) were further analyzed. After characterizing the protein components (SDS-PAGE and western blotting) and morphological analyses (TEM and DLS), we focused on EV-I 20 k-ppt and EV-II 100 k-ppt and subjected them to proteomic analyses.
    Goat Anti Dpp Iv Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/goat anti-dpp-iv antibody/product/R&D Systems
    Average 90 stars, based on 1 article reviews
    goat anti-dpp-iv antibody - by Bioz Stars, 2026-03
    90/100 stars
      Buy from Supplier

    99
    R&D Systems anti dpp iv goat polyclonal antibody
    Figure 1 Immunohistochemical staining for NEP and <t>DPP</t> IV in IHCC and noncancerous liver tissues. Notes: Original magnification ×200. (A and B) NEP and DPP IV strongly positive expression was found in cell membrane and cytoplasm at various levels in IHCC tissues. (C and D) NEP and DPP IV weakly positive expression was found in cell membrane and cytoplasm at various levels in IHCC tissues. (E and F) NEP and DPP IV negative expression in noncancerous liver tissues. Abbreviations: DPP IV, dipeptidyl peptidase IV; IHCC, intrahepatic cholangio carcinoma; NEP, neutral endopeptidase.
    Anti Dpp Iv Goat Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti dpp iv goat polyclonal antibody/product/R&D Systems
    Average 99 stars, based on 1 article reviews
    anti dpp iv goat polyclonal antibody - by Bioz Stars, 2026-03
    99/100 stars
      Buy from Supplier

    Image Search Results


    Flow chart of procedure for isolating salivary extracellular vesicles. Salivary extracellular vesicles (EVs) were isolated using a combination of size-exclusion chromatography and sequential centrifugation. Human whole saliva was centrifuged, and the supernatant was filtrated and then, concentrated using Amicon Ultra-15. The resulting concentrated solution was applied to a size-exclusion column, and the fractions (Fr.) of EV-I and Fr. EV-II were determined from the measurement of OD280, DPP IV activity, and APN activity. Each fraction was collected, filtered, and concentrated by Amicon Ultra-4 to obtain Fr. EV-I and Fr. EV-II. Each pooled fraction was subjected to sequential centrifugation. The precipitate obtained by centrifugation at 20,000 × g (EV-I or EV-II 20 k-ppt) and the precipitate obtained by centrifugation at 100,000 × g (EV-I or EV-II 100 k-ppt) were further analyzed. After characterizing the protein components (SDS-PAGE and western blotting) and morphological analyses (TEM and DLS), we focused on EV-I 20 k-ppt and EV-II 100 k-ppt and subjected them to proteomic analyses.

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: Flow chart of procedure for isolating salivary extracellular vesicles. Salivary extracellular vesicles (EVs) were isolated using a combination of size-exclusion chromatography and sequential centrifugation. Human whole saliva was centrifuged, and the supernatant was filtrated and then, concentrated using Amicon Ultra-15. The resulting concentrated solution was applied to a size-exclusion column, and the fractions (Fr.) of EV-I and Fr. EV-II were determined from the measurement of OD280, DPP IV activity, and APN activity. Each fraction was collected, filtered, and concentrated by Amicon Ultra-4 to obtain Fr. EV-I and Fr. EV-II. Each pooled fraction was subjected to sequential centrifugation. The precipitate obtained by centrifugation at 20,000 × g (EV-I or EV-II 20 k-ppt) and the precipitate obtained by centrifugation at 100,000 × g (EV-I or EV-II 100 k-ppt) were further analyzed. After characterizing the protein components (SDS-PAGE and western blotting) and morphological analyses (TEM and DLS), we focused on EV-I 20 k-ppt and EV-II 100 k-ppt and subjected them to proteomic analyses.

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques: Isolation, Size-exclusion Chromatography, Centrifugation, Activity Assay, SDS Page, Western Blot

    Preparation of EVs derived from human whole saliva. (upper) Size-exclusion chromatography (Sephacryl S-1000 SF) elution profiles of the EVs from fresh human WS (donor A). The filtrated and concentrated WS (1.5–2.0 mL) was subjected to size-exclusion chromatography on a Sephacryl S-1000 SF column (1.5 cm × 50 cm, 0.33 mL/min) equilibrated with Tris-buffered saline (20 mM Tris-HCl, pH 7.4, and 150 mM NaCl), and 80 fractions (1.2 mL/fraction) were collected within 4 h. All fractions were analyzed for DPP IV and APN activities, and absorbance at 280 nm. The experiments were performed at least three times for each donor, and a representative elution pattern is shown. (lower) Western blot analysis of proteins located on the outer surface (MUC5B and IgA), membrane (MUC1, APN, DPP IV, and CD9), and inner lumen (Alix, TSG101, ezrin, and Annexin A1) of the salivary EV fractions eluted from size-exclusion columns (donor A). Numbers refer to the different fractions obtained via size-exclusion column chromatography shown in the upper panel. Overall, 20 µL of each EV fraction was subjected to SDS-PAGE and analyzed using western blotting. The elution profiles and western blotting of EVs from other donors are shown in .

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: Preparation of EVs derived from human whole saliva. (upper) Size-exclusion chromatography (Sephacryl S-1000 SF) elution profiles of the EVs from fresh human WS (donor A). The filtrated and concentrated WS (1.5–2.0 mL) was subjected to size-exclusion chromatography on a Sephacryl S-1000 SF column (1.5 cm × 50 cm, 0.33 mL/min) equilibrated with Tris-buffered saline (20 mM Tris-HCl, pH 7.4, and 150 mM NaCl), and 80 fractions (1.2 mL/fraction) were collected within 4 h. All fractions were analyzed for DPP IV and APN activities, and absorbance at 280 nm. The experiments were performed at least three times for each donor, and a representative elution pattern is shown. (lower) Western blot analysis of proteins located on the outer surface (MUC5B and IgA), membrane (MUC1, APN, DPP IV, and CD9), and inner lumen (Alix, TSG101, ezrin, and Annexin A1) of the salivary EV fractions eluted from size-exclusion columns (donor A). Numbers refer to the different fractions obtained via size-exclusion column chromatography shown in the upper panel. Overall, 20 µL of each EV fraction was subjected to SDS-PAGE and analyzed using western blotting. The elution profiles and western blotting of EVs from other donors are shown in .

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques: Derivative Assay, Size-exclusion Chromatography, Saline, Western Blot, Membrane, Column Chromatography, SDS Page

    Sequential centrifugation of two types of salivary EVs. Salivary Fr. EV-I and Fr. EV-II were subjected to sequential centrifugation . (A) From each fraction, samples of 2 µg of protein were subjected to SDS-PAGE and silver staining (donor A) was performed to visualize the bands. The silver staining of EVs from other donors is shown in . Grey arrowheads, protein bands shared by Fr. EV-I and Fr. EV-II; black arrowhead, observed predominantly in Fr. EV-I; open arrowheads, observed predominantly in Fr. EV-II. (B) Western blot analysis of proteins located on the outer surface (MUC5B and IgA), membrane (MUC1, APN, DPP IV, and CD9), and inner lumen (Alix, TSG101, ezrin, and Annexin A1) of salivary EVs (donor A). From each EV fraction, samples of 2 µg of protein were subjected to SDS-PAGE, transferred onto PVDF membranes, and immunoblotted with antibodies. Western blots of EVs from other donors are shown in . (C) Morphological analysis of salivary EV fractions visualized using an electron microscope (donor A). Scale bar, 100 nm. The morphology of EVs from other donors is shown in . (D) Particle sizes of salivary EVs analyzed via dynamic light scattering (DLS) measurements conducted in triplicate. A typical result is shown (donor A). The mean particle size of EV-I 20 k-ppt was 263 ± 30 nm (7–14 experiments) and that of EV-II 100 k-ppt was 36.5 ± 13 nm (three to six experiments) .

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: Sequential centrifugation of two types of salivary EVs. Salivary Fr. EV-I and Fr. EV-II were subjected to sequential centrifugation . (A) From each fraction, samples of 2 µg of protein were subjected to SDS-PAGE and silver staining (donor A) was performed to visualize the bands. The silver staining of EVs from other donors is shown in . Grey arrowheads, protein bands shared by Fr. EV-I and Fr. EV-II; black arrowhead, observed predominantly in Fr. EV-I; open arrowheads, observed predominantly in Fr. EV-II. (B) Western blot analysis of proteins located on the outer surface (MUC5B and IgA), membrane (MUC1, APN, DPP IV, and CD9), and inner lumen (Alix, TSG101, ezrin, and Annexin A1) of salivary EVs (donor A). From each EV fraction, samples of 2 µg of protein were subjected to SDS-PAGE, transferred onto PVDF membranes, and immunoblotted with antibodies. Western blots of EVs from other donors are shown in . (C) Morphological analysis of salivary EV fractions visualized using an electron microscope (donor A). Scale bar, 100 nm. The morphology of EVs from other donors is shown in . (D) Particle sizes of salivary EVs analyzed via dynamic light scattering (DLS) measurements conducted in triplicate. A typical result is shown (donor A). The mean particle size of EV-I 20 k-ppt was 263 ± 30 nm (7–14 experiments) and that of EV-II 100 k-ppt was 36.5 ± 13 nm (three to six experiments) .

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques: Centrifugation, SDS Page, Silver Staining, Western Blot, Membrane, Microscopy

    Isolation profiles of salivary EVs from Fr. EV-I or Fr. EV-II by sequential centrifugation.

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: Isolation profiles of salivary EVs from Fr. EV-I or Fr. EV-II by sequential centrifugation.

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques: Isolation, Centrifugation, Activity Assay

    Characteristic proteins in salivary EVs.

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: Characteristic proteins in salivary EVs.

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques:

    MUC1, DPP IV, and CD9 were expressed on the surface of salivary EVs. Immunoprecipitation of salivary EVs. Salivary EVs (Fr. EV-I or Fr. EV-II) were immunoprecipitated using magnetic beads. Antibody-coupled beads were added to 5 μg of EVs and the mixture was incubated at 4°C for 18 h on a rotator. The proteins eluted from the beads were subjected to SDS-PAGE. Western blots of EVs from other donors are shown in . Immunoprecipitation with an anti-APN antibody is shown in .

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: MUC1, DPP IV, and CD9 were expressed on the surface of salivary EVs. Immunoprecipitation of salivary EVs. Salivary EVs (Fr. EV-I or Fr. EV-II) were immunoprecipitated using magnetic beads. Antibody-coupled beads were added to 5 μg of EVs and the mixture was incubated at 4°C for 18 h on a rotator. The proteins eluted from the beads were subjected to SDS-PAGE. Western blots of EVs from other donors are shown in . Immunoprecipitation with an anti-APN antibody is shown in .

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques: Immunoprecipitation, Magnetic Beads, Incubation, SDS Page, Western Blot

    Sequential immunoprecipitation of salivary EVs. (A) Flow chart of procedure for sequential immunoprecipitation. Two types of salivary EVs were sequentially immunoprecipitated from the WS using magnetic beads. Pretreated WS (1 mL) was incubated with anti-DPP IV antibody-coupled beads at 4°C for 3 h on a rotator (first immunoprecipitation). After separating the beads, the WS was further incubated with anti-MUC1 antibody-coupled beads (second immunoprecipitation) at 4°C for 18 h. For the control experiment, nonspecific goat IgG-conjugated magnetic beads and nonspecific mouse IgG-conjugated beads were used for the first and second immunoprecipitations, respectively. The immunoprecipitated beads were washed with PBS, and then sample buffer (20 μL) was added and the solution was denatured at 70°C for 10 min. The eluates were then subjected to western blot analysis. (B) Western blot analysis of the proteins located on the membrane (MUC1, APN, DPP IV and CD9) and inner lumen (Alix and ezrin) of the salivary EVs (donor A). Western blots of EVs from other donors are shown in .

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: Sequential immunoprecipitation of salivary EVs. (A) Flow chart of procedure for sequential immunoprecipitation. Two types of salivary EVs were sequentially immunoprecipitated from the WS using magnetic beads. Pretreated WS (1 mL) was incubated with anti-DPP IV antibody-coupled beads at 4°C for 3 h on a rotator (first immunoprecipitation). After separating the beads, the WS was further incubated with anti-MUC1 antibody-coupled beads (second immunoprecipitation) at 4°C for 18 h. For the control experiment, nonspecific goat IgG-conjugated magnetic beads and nonspecific mouse IgG-conjugated beads were used for the first and second immunoprecipitations, respectively. The immunoprecipitated beads were washed with PBS, and then sample buffer (20 μL) was added and the solution was denatured at 70°C for 10 min. The eluates were then subjected to western blot analysis. (B) Western blot analysis of the proteins located on the membrane (MUC1, APN, DPP IV and CD9) and inner lumen (Alix and ezrin) of the salivary EVs (donor A). Western blots of EVs from other donors are shown in .

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques: Immunoprecipitation, Magnetic Beads, Incubation, Control, Western Blot, Membrane

    Schematic model of the components of salivary EVs (EV-I and EV-II). Two distinct populations of EVs are present in human WS: large-sized, APN/MUC1-rich, m/l/EVs/microvesicles (EV-I), and small-sized DPP IV/CD9-rich vesicles containing several sEV components (EV-II).

    Journal: Frontiers in Molecular Biosciences

    Article Title: Distinguishing two distinct types of salivary extracellular vesicles: a potential tool for understanding their pathophysiological roles

    doi: 10.3389/fmolb.2024.1278955

    Figure Lengend Snippet: Schematic model of the components of salivary EVs (EV-I and EV-II). Two distinct populations of EVs are present in human WS: large-sized, APN/MUC1-rich, m/l/EVs/microvesicles (EV-I), and small-sized DPP IV/CD9-rich vesicles containing several sEV components (EV-II).

    Article Snippet: Plates were then washed three times with Tris-buffered saline (TBS) with 0.05% Tween 20 (TTBS) and incubated with 50 μL of mouse anti-APN antibody (Santa Cruz Biotechnology, Inc.) for EV-I or goat anti-DPP IV antibody (R&D Systems, Inc.) for EV-II diluted 1:1,000 with 1% BSA–PBS overnight at 4°C.

    Techniques:

    Figure 1 Immunohistochemical staining for NEP and DPP IV in IHCC and noncancerous liver tissues. Notes: Original magnification ×200. (A and B) NEP and DPP IV strongly positive expression was found in cell membrane and cytoplasm at various levels in IHCC tissues. (C and D) NEP and DPP IV weakly positive expression was found in cell membrane and cytoplasm at various levels in IHCC tissues. (E and F) NEP and DPP IV negative expression in noncancerous liver tissues. Abbreviations: DPP IV, dipeptidyl peptidase IV; IHCC, intrahepatic cholangio carcinoma; NEP, neutral endopeptidase.

    Journal: OncoTargets and Therapy

    Article Title: Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection

    doi: 10.2147/ott.s57355

    Figure Lengend Snippet: Figure 1 Immunohistochemical staining for NEP and DPP IV in IHCC and noncancerous liver tissues. Notes: Original magnification ×200. (A and B) NEP and DPP IV strongly positive expression was found in cell membrane and cytoplasm at various levels in IHCC tissues. (C and D) NEP and DPP IV weakly positive expression was found in cell membrane and cytoplasm at various levels in IHCC tissues. (E and F) NEP and DPP IV negative expression in noncancerous liver tissues. Abbreviations: DPP IV, dipeptidyl peptidase IV; IHCC, intrahepatic cholangio carcinoma; NEP, neutral endopeptidase.

    Article Snippet: Subsequently, the slides were incubated overnight with the primary antibodies against anti-NEP mouse monoclonal antibody (#sc-46656; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or anti-DPP IV goat polyclonal antibody (#AF1180, R&D Systems, Minneapolis, MN, USA) at 4°C.

    Techniques: Immunohistochemical staining, Staining, Expressing, Membrane

    Figure 2 Overall survival and recurrence-free survival curves for two groups defined by low and high expression of NEP or DPP IV, and for four groups defined by combined expression of NEP and DPP IV, of patients with IHCC. Notes: Kaplan–Meier analysis showed IHCC patients with high NEP expression, high DPP IV expression, and combined overexpression of NEP and DPP IV proteins all had poorer overall survival and early recurrence after surgery. (A and B) low and high expression of NEP. (C and D) low and high expression DPP IV. (E and F) combined expression of NEP and DPP IV. Abbreviations: DPP IV, dipeptidyl peptidase IV; IHCC, intrahepatic cholangiocarcinoma; NEP, neutral endopeptidase.

    Journal: OncoTargets and Therapy

    Article Title: Prognostic significance of the combined expression of neutral endopeptidase and dipeptidyl peptidase IV in intrahepatic cholangiocarcinoma patients after surgery resection

    doi: 10.2147/ott.s57355

    Figure Lengend Snippet: Figure 2 Overall survival and recurrence-free survival curves for two groups defined by low and high expression of NEP or DPP IV, and for four groups defined by combined expression of NEP and DPP IV, of patients with IHCC. Notes: Kaplan–Meier analysis showed IHCC patients with high NEP expression, high DPP IV expression, and combined overexpression of NEP and DPP IV proteins all had poorer overall survival and early recurrence after surgery. (A and B) low and high expression of NEP. (C and D) low and high expression DPP IV. (E and F) combined expression of NEP and DPP IV. Abbreviations: DPP IV, dipeptidyl peptidase IV; IHCC, intrahepatic cholangiocarcinoma; NEP, neutral endopeptidase.

    Article Snippet: Subsequently, the slides were incubated overnight with the primary antibodies against anti-NEP mouse monoclonal antibody (#sc-46656; Santa Cruz Biotechnology, Inc., Dallas, TX, USA) or anti-DPP IV goat polyclonal antibody (#AF1180, R&D Systems, Minneapolis, MN, USA) at 4°C.

    Techniques: Expressing, Over Expression